Download PDF
Thromb Haemost 2009; 102(03): 609-610
DOI: 10.1160/TH09-04-0257
Letters to the Editor
Schattauer GmbH

Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)

Ann Gils
1   Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
,
Lester M. Meissenheimer
1   Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
,
Griet Compernolle
1   Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
,
Paul J. Declerck
1   Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium
› Author AffiliationsFinancial support: Lester M. Meissenheimer was supported by a National Research Foundation (NRF) (South Africa) studentship. This work was supported by the grant G.0540.08 of the fund for Scientific Research-Flanders.
Further Information

Publication History

Received: 22 April 2009

Accepted after minor revision: 16 June 2009

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 03: 35-45.
    CrossrefPubMedSearch in Google Scholar
  • 2 Hennan JK, Morgan GA, Swillo RE. et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008; 06: 1558-1564.
    PubMedSearch in Google Scholar
  • 3 Suzuki J, Ogawa M, Muto S. et al. The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. Expert Opin Ther Targets 2008; 12: 783-794.
    CrossrefPubMedSearch in Google Scholar
  • 4 Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-2738.
    CrossrefPubMedSearch in Google Scholar
  • 5 Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91: 425-437.
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Ngo TH, Zhou Y, Stassen JM. et al. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition. Thromb Haemost 2002; 88: 288-293.
    Thieme ConnectPubMedSearch in Google Scholar